Epidermal growth factor receptor (EGFR) mutation is the most common driver mutation in
non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients …

Alternative splicing of pre‐messenger RNA (mRNA) is a fundamental mechanism by which a
gene can give rise to multiple distinct mRNA transcripts, yielding protein isoforms with …

Identification of driver genes contributes to the understanding of cancer etiology and is
imperative for the development of individualized therapies. Gene amplification is a major …

Inactivation of epidermal growth factor receptor (EGFR) family members represents a
promising strategy for the development of selective therapies against epithelial cancers …

Introduction The epidermal growth factor (EGF) signaling system regulates trophoblast
differentiation, and its disruption could contribute to perinatal disease. We hypothesized that …

Targeting wild-type epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) never achieved its purported success in cancers such as head and neck squamous …

Disturbed alternative splicing is a common feature of human tumors. Splicing factors that
control alternative splicing are phosphorylated by multiple kinases, including these that …

Placental dysfunction is the underlying cause of pregnancy complications such as fetal
growth restriction (FGR) and pre-eclampsia. No therapies are available to treat a poorly …

The epidermal growth factor receptor (EGFR) is expressed robustly in the placenta, and
critical processes of pregnancy such as placental growth and trophoblast fusion are …

Alternative splicing is known to remodel protein-protein interaction networks
(“interactomes”), yet large-scale determination of isoform-specific interactions remains …